GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...
1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles [1] People ...
New York Post on MSN3d
FDA proposes ending use of popular decongestant in cold medicinesThe US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
(Reuters) -The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback